Leucoderma is a broad term for any white or light-colored patch on the skin caused by a loss of pigment. It is not a single disease but a description: wherever the cells that produce melanin (the pigment that gives skin its color) are damaged or destroyed, the skin turns pale or white. The most common and well-known form is vitiligo, an autoimmune condition, but leucoderma can also be triggered by chemical exposure, burns, infections, or skin injuries. Globally, vitiligo alone affects an estimated 28.5 million people, with a lifetime prevalence of about 0.36% of the general population.
How Leucoderma Differs From Vitiligo
In everyday conversation and even in many medical settings, “leucoderma” and “vitiligo” are used interchangeably. Technically, leucoderma is the broader umbrella. Vitiligo is a specific autoimmune form where the immune system attacks pigment-producing cells. Chemical leucoderma, by contrast, is depigmentation triggered by repeated exposure to certain chemicals. In practice, the line between the two can be blurry. Chemical leucoderma can evolve into widespread vitiligo, and the underlying biological processes overlap enough that some researchers consider chemical leucoderma a subtype of vitiligo rather than a separate condition.
What Causes It
The root cause is always damage to melanocytes, the cells responsible for skin color. What varies is the source of that damage.
Autoimmune Vitiligo
In the most common form, the body’s own immune system mistakenly targets melanocytes. Genetics play a significant role: people with a family history of vitiligo or other autoimmune conditions (thyroid disease, type 1 diabetes, alopecia areata) are at higher risk. The condition can begin at any age but often first appears in early adulthood.
Chemical Leucoderma
This form is triggered by repeated skin contact with, or sometimes ingestion or inhalation of, chemicals that are toxic to melanocytes. The causative agents are mostly phenol and catechol derivatives. These chemicals generate oxidative stress inside melanocytes, overwhelming the cell’s ability to neutralize damaging molecules. Crucially, not everyone exposed to these chemicals develops white patches. It happens in people with a specific genetic susceptibility, which is why researchers see it as closely related to vitiligo.
Household and personal care products are surprisingly common culprits. Hair dyes containing paraphenylenediamine (PPD), adhesives in stick-on forehead decorations (bindis), rubber slippers, synthetic leather wallets held against the skin, watch straps, hearing aids, latex condoms, and even certain toothpastes have all been documented as triggers. A skin-lightening cream sold by a Japanese cosmetics company caused vitiligo-like depigmentation in roughly 16,000 users, about 2% of everyone who used it. The active ingredient was a phenol-related compound called rhododendrol.
Other Triggers
Burns, cuts, and chronic friction can destroy melanocytes in the affected area, leaving behind lighter skin. Some infections and inflammatory skin conditions can also produce white patches as they heal. These post-inflammatory forms of leucoderma are generally localized to the site of injury.
What the Patches Look and Feel Like
The hallmark is a flat, chalky-white patch with clearly defined edges. The skin itself feels normal to the touch and does not flake or scale. Patches tend to appear first on areas that get a lot of sun exposure or friction: fingertips, knuckles, around the lips and eyes, toes, elbows, forearms, and the genital area.
In generalized vitiligo, the patches are strikingly symmetrical. A spot on the left forearm often has a matching one on the right. This pattern can spread sporadically over months or years, sometimes staying stable for long stretches and then progressing again. Segmental vitiligo, a less common form, affects only one side of the body. It typically starts in childhood, spreads for one to two years, and then stabilizes permanently.
In chemical leucoderma, patches usually appear first at the site of chemical contact, often preceded by mild irritation or a rash. “Confetti-like” tiny white spots are a characteristic early sign, though these can also appear in early-stage vitiligo.
How It Is Diagnosed
A dermatologist can often identify leucoderma through a visual examination alone. The combination of chalky-white, non-scaly patches in a characteristic distribution is usually distinctive enough for a confident diagnosis.
A Wood’s lamp, a handheld ultraviolet light, is one of the most useful tools. Under this light, depigmented skin glows bright chalky white, making patches visible even in very fair-skinned individuals where they might otherwise be hard to spot. This also helps distinguish true pigment loss from conditions where pigment is merely reduced rather than absent.
Additional tests may include blood work to screen for associated autoimmune conditions like thyroid disease, an eye exam to check for uveitis (inflammation inside the eye that occasionally accompanies vitiligo), and in ambiguous cases, a small skin biopsy. Under a microscope, affected skin shows a clear absence of melanocytes, confirming the diagnosis.
Who Is Most Affected
Vitiligo occurs across all ethnic groups and skin tones, but its visibility and psychosocial impact are greatest in people with darker skin. Central Europe and South Asia report the highest prevalence, each at about 0.52% of the general population. Adults are affected more often than children. About 5.8 million children worldwide have vitiligo compared to 37.1 million adults. There is no difference in rates between men and women, though women tend to seek treatment more often.
Treatment Options
No single treatment works for everyone, and repigmentation is a slow process that typically takes months to years. The goal of most therapies is to coax melanocytes in surrounding healthy skin to migrate into the white patches and begin producing pigment again.
Topical Creams
For limited areas, prescription creams are the usual starting point. Topical corticosteroids reduce the immune attack on melanocytes. Calcineurin inhibitors (a class of immune-modulating cream) are often preferred for sensitive areas like the face and eyelids because they don’t carry the skin-thinning risk of steroids. One clinical study found that applying a calcineurin inhibitor twice daily for seven months measurably reduced oxidative stress in the skin and improved antioxidant activity.
Light Therapy
Narrowband UVB phototherapy is one of the most widely used treatments for widespread vitiligo. Sessions are typically done two to three times per week in a clinic, and a minimum of 12 weeks or 24 sessions is generally needed before results can be fairly evaluated. Longer courses tend to produce better responses, but the time commitment is significant, and outcomes can be inconsistent. Some patients see substantial repigmentation; others see little change.
A Newer Prescription Option
In 2022, the FDA approved a topical cream containing ruxolitinib, making it the first pharmacologic treatment specifically approved for repigmentation in vitiligo. It works by blocking an immune signaling pathway (JAK pathway) involved in the destruction of melanocytes. In clinical trials, 30% of patients achieved at least 75% improvement in facial depigmentation after 24 weeks, compared to 10% on placebo. The label notes that a satisfactory response may require more than 24 weeks of use. It is approved for patients 12 years and older with the nonsegmental form of the disease.
Surgical Approaches for Stable Patches
When patches have been completely stable for at least a year and no longer respond to creams or light therapy, melanocyte transplantation becomes an option. The procedure involves taking a small sample of the patient’s own pigmented skin, separating out the melanocytes, and placing them onto the depigmented area. A meta-analysis of 17 studies covering nearly 1,200 patients found that transplantation combined with follow-up light therapy produced significantly better results than transplantation alone. Both cultured and non-cultured cell techniques showed similar effectiveness.
Chemical Leucoderma: Identification and Prevention
If your white patches appeared at the site where a product regularly touches your skin, chemical leucoderma is worth investigating. Common clues include depigmentation on the forehead from adhesive bindis, on the feet from rubber footwear, on the hands from rubber gloves, or around the hairline from hair dye. Many patients recall a period of mild redness or irritation at the site before the white patch developed.
Identifying and removing the offending chemical is the most important step. In many cases, especially when caught early, some degree of repigmentation occurs naturally once the trigger is eliminated. If patches have already spread beyond the contact site, treatment follows the same approach used for autoimmune vitiligo: topical creams, light therapy, or both.
Emotional and Social Impact
Leucoderma is not physically painful or medically dangerous, but its psychological effects can be profound. Visible depigmentation, particularly on the face and hands, leads to self-consciousness, social anxiety, and in some cultures, significant stigma. The impact is especially pronounced in people with darker skin, where the contrast between pigmented and depigmented areas is most visible. Addressing the emotional dimension is as important as treating the skin itself, and connecting with support communities or a mental health professional can make a real difference in quality of life.